<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer-Verlag</PublisherName>
    <PublisherLocation>New York</PublisherLocation>
  </PublisherInfo>
  <Journal>
    <JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered">
      <JournalID>12248</JournalID>
      <JournalElectronicISSN>1550-7416</JournalElectronicISSN>
      <JournalTitle>The AAPS Journal</JournalTitle>
      <JournalAbbreviatedTitle>AAPS J</JournalAbbreviatedTitle>
      <JournalSubjectGroup>
        <JournalSubject Code="F" Type="Primary">Pharmacy</JournalSubject>
        <JournalSubject Code="F00008" Priority="1" Type="Secondary">Pharmacy</JournalSubject>
        <JournalSubject Code="B21007" Priority="2" Type="Secondary">Pharmacology/Toxicology</JournalSubject>
        <JournalSubject Code="C12002" Priority="3" Type="Secondary">Biotechnology</JournalSubject>
      </JournalSubjectGroup>
    </JournalInfo>
    <Volume>
      <VolumeInfo TocLevels="0" VolumeType="Regular">
        <VolumeIDStart>7</VolumeIDStart>
        <VolumeIDEnd>7</VolumeIDEnd>
        <VolumeIssueCount>4</VolumeIssueCount>
      </VolumeInfo>
      <Issue IssueType="Regular">
        <IssueInfo TocLevels="0">
          <IssueIDStart>1</IssueIDStart>
          <IssueIDEnd>1</IssueIDEnd>
          <IssueArticleCount>25</IssueArticleCount>
          <IssueHistory>
            <CoverDate>
              <Year>2005</Year>
              <Month>3</Month>
            </CoverDate>
          </IssueHistory>
          <IssueCopyright>
            <CopyrightHolderName>American Association of Pharmaceutical Scientists</CopyrightHolderName>
            <CopyrightYear>2005</CopyrightYear>
          </IssueCopyright>
        </IssueInfo>
        <Article ID="Art3">
          <ArticleInfo ArticleType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0">
            <ArticleID>71014</ArticleID>
            <ArticleDOI>10.1208/aapsj070103</ArticleDOI>
            <ArticleSequenceNumber>3</ArticleSequenceNumber>
            <ArticleTitle Language="En">Properties of thalidomide and its analogues: Implications for anticancer therapy</ArticleTitle>
            <ArticleFirstPage>E14</ArticleFirstPage>
            <ArticleLastPage>E19</ArticleLastPage>
            <ArticleHistory>
              <RegistrationDate>
                <Year>2008</Year>
                <Month>1</Month>
                <Day>28</Day>
              </RegistrationDate>
              <Received>
                <Year>2004</Year>
                <Month>5</Month>
                <Day>28</Day>
              </Received>
              <Accepted>
                <Year>2005</Year>
                <Month>1</Month>
                <Day>26</Day>
              </Accepted>
            </ArticleHistory>
            <ArticleCopyright>
              <CopyrightHolderName>American Association of Pharmaceutical Scientists</CopyrightHolderName>
              <CopyrightYear>2005</CopyrightYear>
            </ArticleCopyright>
            <ArticleGrants Type="Regular">
              <MetadataGrant Grant="OpenAccess"/>
              <AbstractGrant Grant="OpenAccess"/>
              <BodyPDFGrant Grant="Restricted"/>
              <BodyHTMLGrant Grant="Restricted"/>
              <BibliographyGrant Grant="Restricted"/>
              <ESMGrant Grant="Restricted"/>
            </ArticleGrants>
            <ArticleContext>
              <JournalID>12248</JournalID>
              <VolumeIDStart>7</VolumeIDStart>
              <VolumeIDEnd>7</VolumeIDEnd>
              <IssueIDStart>1</IssueIDStart>
              <IssueIDEnd>1</IssueIDEnd>
            </ArticleContext>
          </ArticleInfo>
          <ArticleHeader>
            <AuthorGroup>
              <Author AffiliationIDS="Aff1" CorrespondingAffiliationID="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Steven</GivenName>
                  <GivenName>K.</GivenName>
                  <FamilyName>Teo</FamilyName>
                </AuthorName>
                <Contact>
                  <Phone>(908) 673-9320</Phone>
                  <Fax>(908) 673-2792</Fax>
                  <Email>steo@celgene.com</Email>
                </Contact>
              </Author>
              <Affiliation ID="Aff1">
                <OrgName>Celgene Corporation</OrgName>
                <OrgAddress>
                  <Postcode>07901</Postcode>
                  <City>Summit</City>
                  <State>NJ</State>
                </OrgAddress>
              </Affiliation>
            </AuthorGroup>
            <Abstract ID="Abs1" Language="En">
              <Heading>Abstract</Heading>
              <Para>Thalidomide and its immunomodulatory (IMiDs) analogs (lenalidomide, Revlimid, CC-5013; CC-4047, ACTIMID) are a novel class of compounds with numerous effects on the body's immune system, some of which are thought to mediate the anticancer and anti-inflammatory results observed in humans. Thalidomide is currently being used experimentally to treat various cancers and inflammatory diseases. It is approved for the treatment of dermal, reaction from leprosy and is currently in phase III trials for multiple myeloma. Thalidomide and IMiDs inhibit the cytokines tumor necrosis factor-α (TNF-α), interleukins (IL) 1β, 6, 12, and granulocyte macrophagecolony stimulating factor (GM-CSF). They also costimulate primary human T lymphocytes inducing their proliferation, cytokine production, and cytotoxic activity thereby increasing the T cells' anticancer activity. They induce an IL-2-mediated primary T cell proliferation with a concomitant increase in IFN-γ production and decrease the density of TNF-α-induced cell surface adhesion molecules ICAM-1, VCAM-1, and E-selectin on human umbilical vein endothelial cells. Thalidomide stimulates the Th-1 response increasing, IFN-γ levels while CC-4047 increased IL-2 as well. Some of the above immunomodulatory activities along with anti-angiogenic, anti-proliferative, and pro-apoptotic properties are thought to mediate the IMiDs' antitumor responses observed in relapsed and refractory multiple myeloma and some solid tumor cancers. This has led to their use in various oncology clinical trials. The second generation IMiD, lenalidomide, has shown potential in treating the bone marrow disorders myelodysplastic syndrome and multiple myeloma. It is currently in phase II and III trials for these diseases respectively with numer-ous phase II trials in other hematologic and solid tumors.</Para>
            </Abstract>
            <KeywordGroup Language="En">
              <Heading>Keywords</Heading>
              <Keyword>Thalidomide</Keyword>
              <Keyword>lenalidomide</Keyword>
              <Keyword>IMiDs</Keyword>
              <Keyword>immunomodulatory</Keyword>
              <Keyword>cytokine</Keyword>
              <Keyword>multiple myeloma</Keyword>
              <Keyword>anti-cancer</Keyword>
            </KeywordGroup>
            <ArticleNote Type="Misc">
              <SimplePara>Published: March 22, 2005.</SimplePara>
            </ArticleNote>
            <ArticleNote Type="PresentedAt">
              <SimplePara>This review is based on a presentation at the AAPS workshop on “Exposure Response Relationships of Immunemodulators,” March 27–28, 2003, Washington, DC.</SimplePara>
            </ArticleNote>
          </ArticleHeader>
          <BodyRef FileRef="BodyRef/PDF/12248_2008_Article_71014.pdf" TargetType="OnlinePDF"/>
          <ArticleBackmatter>
            <Bibliography ID="Bib1">
              <Heading>References</Heading>
              <Citation ID="CR1">
                <CitationNumber>1.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Teo</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Resztak</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Scheffler</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Thalidomide in the treatment of leprosy</ArticleTitle>
                  <JournalTitle>Microbes Infect</JournalTitle>
                  <VolumeID>4</VolumeID>
                  <FirstPage>1193</FirstPage>
                  <LastPage>1202</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12361920</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S1286-4579(02)01645-3</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XnsVansbc%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Teo S, Resztak K, Scheffler M, et al. Thalidomide in the treatment of leprosy.<Emphasis Type="Italic">Microbes Infect</Emphasis>. 2002;4:1193–1202.</BibUnstructured>
              </Citation>
              <Citation ID="CR2">
                <CitationNumber>2.</CitationNumber>
                <BibBook>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Stephens</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Brynner</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <BookTitle>Dark Remedy: The Impact of Thalidomide and Its Revival as a Vital Medicine</BookTitle>
                  <PublisherName>Perseus Publishing</PublisherName>
                  <PublisherLocation>Cambridge, MA</PublisherLocation>
                </BibBook>
                <BibUnstructured>Stephens T, Brynner R.<Emphasis Type="Italic">Dark Remedy: The Impact of Thalidomide and Its Revival as a Vital Medicine</Emphasis>. Cambridge, MA: Perseus Publishing; 2001.</BibUnstructured>
              </Citation>
              <Citation ID="CR3">
                <CitationNumber>3.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>G.</Initials>
                    <FamilyName>Mellin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Katzenstein</FamilyName>
                  </BibAuthorName>
                  <Year>1962</Year>
                  <ArticleTitle Language="En">The saga of thalidomide: neuropathy to embryopathy with case reports and congenital abnormalities</ArticleTitle>
                  <JournalTitle>N Engl J Med</JournalTitle>
                  <VolumeID>267</VolumeID>
                  <FirstPage>1184</FirstPage>
                  <LastPage>1193</LastPage>
                  <Occurrence Type="PID">
                    <Handle>13934699</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaF2cXnvVShtQ%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1056/NEJM196212062672305</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Mellin G., Katzenstein M. The saga of thalidomide: neuropathy to embryopathy with case reports and congenital abnormalities.<Emphasis Type="Italic">N Engl J Med</Emphasis>. 1962;267:1184–1193.</BibUnstructured>
              </Citation>
              <Citation ID="CR4">
                <CitationNumber>4.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Kelsey</FamilyName>
                  </BibAuthorName>
                  <Year>1988</Year>
                  <ArticleTitle Language="En">Thalidomide update: regulatory aspects</ArticleTitle>
                  <JournalTitle>Teratology</JournalTitle>
                  <VolumeID>38</VolumeID>
                  <FirstPage>221</FirstPage>
                  <LastPage>226</LastPage>
                  <Occurrence Type="PID">
                    <Handle>3227491</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/tera.1420380305</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaL1M7ks1Kksw%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kelsey F. Thalidomide update: regulatory aspects.<Emphasis Type="Italic">Teratology</Emphasis>. 1988;38:221–226.</BibUnstructured>
              </Citation>
              <Citation ID="CR5">
                <CitationNumber>5.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Newman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Johnson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Staples</FamilyName>
                  </BibAuthorName>
                  <Year>1993</Year>
                  <ArticleTitle Language="En">Assessment of the effectiveness of animal developmental toxicity testing for human safety</ArticleTitle>
                  <JournalTitle>Reprod Toxicol</JournalTitle>
                  <VolumeID>7</VolumeID>
                  <FirstPage>359</FirstPage>
                  <LastPage>390</LastPage>
                  <Occurrence Type="PID">
                    <Handle>8400625</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0890-6238(93)90025-3</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2cXhsFarsrw%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Newman L, Johnson E, Staples R. Assessment of the effectiveness of animal developmental toxicity testing for human safety.<Emphasis Type="Italic">Reprod Toxicol</Emphasis>. 1993;7:359–390.</BibUnstructured>
              </Citation>
              <Citation ID="CR6">
                <CitationNumber>6.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Zeldis</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Williams</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Thomas</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Elsayed</FamilyName>
                  </BibAuthorName>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">STEPS<Superscript>™</Superscript>: a comprehensive program for controlling and monitoring access to thalidomide</ArticleTitle>
                  <JournalTitle>Clin Ther</JournalTitle>
                  <VolumeID>21</VolumeID>
                  <FirstPage>319</FirstPage>
                  <LastPage>330</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10211535</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0149-2918(00)88289-2</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaK1M3is1GitQ%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Zeldis J, Williams B, Thomas S, Elsayed M. STEPS<Superscript>™</Superscript>: a comprehensive program for controlling and monitoring access to thalidomide.<Emphasis Type="Italic">Clin Ther</Emphasis>. 1999;21:319–330.</BibUnstructured>
              </Citation>
              <Citation ID="CR7">
                <CitationNumber>7.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Raje</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Anderson</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Thalidomide and immunomodulatory drugs as cancer therapy</ArticleTitle>
                  <JournalTitle>Curr Opin Oncol</JournalTitle>
                  <VolumeID>14</VolumeID>
                  <FirstPage>635</FirstPage>
                  <LastPage>640</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12409654</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1097/00001622-200211000-00008</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XosFegtLg%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Raje N, Anderson K. Thalidomide and immunomodulatory drugs as cancer therapy.<Emphasis Type="Italic">Curr Opin Oncol</Emphasis>. 2002;14:635–640.</BibUnstructured>
              </Citation>
              <Citation ID="CR8">
                <CitationNumber>8.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Singhal</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Mehta</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Desikan</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">Anti-tumor activity of thalidomide in refractory multiple myeloma</ArticleTitle>
                  <JournalTitle>N Engl J Med</JournalTitle>
                  <VolumeID>341</VolumeID>
                  <FirstPage>1565</FirstPage>
                  <LastPage>1571</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10564685</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1056/NEJM199911183412102</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1MXotVSgs78%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Singhal S, Mehta J, Desikan R, et al. Anti-tumor activity of thalidomide in refractory multiple myeloma.<Emphasis Type="Italic">N Engl J Med</Emphasis>. 1999;341:1565–1571.</BibUnstructured>
              </Citation>
              <Citation ID="CR9">
                <CitationNumber>9.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Drach</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Kaufman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Woehrer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Chott</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Zielinski</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Raderer</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Durable remissions after rituximab plus thalidomide for relapsed/refractory mantle cell lymphoma</ArticleTitle>
                  <JournalTitle>Proc Am Soc Clin Oncol</JournalTitle>
                  <VolumeID>22</VolumeID>
                  <FirstPage>6583</FirstPage>
                  <LastPage>6583</LastPage>
                </BibArticle>
                <BibUnstructured>Drach J, Kaufman H, Woehrer S, Chott A, Zielinski C, Raderer M. Durable remissions after rituximab plus thalidomide for relapsed/refractory mantle cell lymphoma.<Emphasis Type="Italic">Proc Am Soc Clin Oncol</Emphasis>. 2004;22: Abstract 6583.</BibUnstructured>
              </Citation>
              <Citation ID="CR10">
                <CitationNumber>10.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Stirling</FamilyName>
                  </BibAuthorName>
                  <Year>1998</Year>
                  <ArticleTitle Language="En">Thalidomide and its impact on dermatology</ArticleTitle>
                  <JournalTitle>Semin Cutan Med Surg</JournalTitle>
                  <VolumeID>17</VolumeID>
                  <FirstPage>231</FirstPage>
                  <LastPage>242</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9859910</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S1085-5629(98)80019-9</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaK1M%2FnsFamsQ%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Stirling D. Thalidomide and its impact on dermatology.<Emphasis Type="Italic">Semin Cutan Med Surg</Emphasis>. 1998;17:231–242.</BibUnstructured>
              </Citation>
              <Citation ID="CR11">
                <CitationNumber>11.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Vasiliauskas</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Kam</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Abreu-Martin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Papadakis</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Zeldis</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Targan</FamilyName>
                  </BibAuthorName>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">An open-label step-wise dose escalating pilot study to evaluate the safety, tolerance and efficacy of low dose thalidomide in the treatment of chronically-active, steroid-dependent Crohns disease</ArticleTitle>
                  <JournalTitle>Gastroenterol</JournalTitle>
                  <VolumeID>116</VolumeID>
                  <FirstPage>A387</FirstPage>
                  <LastPage>A387</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0016-5085(99)70136-8</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Vasiliauskas E, Kam L, Abreu-Martin M, Papadakis K, Zeldis J, Targan S. An open-label step-wise dose escalating pilot study to evaluate the safety, tolerance and efficacy of low dose thalidomide in the treatment of chronically-active, steroid-dependent Crohns disease.<Emphasis Type="Italic">Gastroenterol</Emphasis>. 1999;116:A387. Abstract G3637.</BibUnstructured>
              </Citation>
              <Citation ID="CR12">
                <CitationNumber>12.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Schey</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Cavenagh</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Johnson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Child</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Oakervee</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RA</Initials>
                    <FamilyName>Jones</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">UK myeloma forum phase III study of thalidomide: long-term follow-up and recommendations for treatment</ArticleTitle>
                  <JournalTitle>Leuk Res</JournalTitle>
                  <VolumeID>27</VolumeID>
                  <FirstPage>909</FirstPage>
                  <LastPage>914</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12860011</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0145-2126(03)00027-4</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXltF2jsL4%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Schey S, Cavenagh J, Johnson R, Child J, Oakervee H, Jones RA. UK myeloma forum phase III study of thalidomide: long-term follow-up and recommendations for treatment.<Emphasis Type="Italic">Leuk Res</Emphasis>. 2003;27:909–914.</BibUnstructured>
              </Citation>
              <Citation ID="CR13">
                <CitationNumber>13.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Fine</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Wen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Maher</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Phase II trial of thalidomide and carmustine for patients with recurrent high-grade glioma</ArticleTitle>
                  <JournalTitle>J Clin Oncol</JournalTitle>
                  <VolumeID>21</VolumeID>
                  <FirstPage>2299</FirstPage>
                  <LastPage>2304</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12805330</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1200/JCO.2003.08.045</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXpsVKjsro%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Fine H, Wen P, Maher E, et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade glioma.<Emphasis Type="Italic">J Clin Oncol</Emphasis>. 2003;21:2299–2304.</BibUnstructured>
              </Citation>
              <Citation ID="CR14">
                <CitationNumber>14.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>W</Initials>
                    <FamilyName>Hwu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Krown</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Menell</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma</ArticleTitle>
                  <JournalTitle>J Clin Oncol</JournalTitle>
                  <VolumeID>21</VolumeID>
                  <FirstPage>3351</FirstPage>
                  <LastPage>3356</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12947072</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1200/JCO.2003.02.061</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXps1akurc%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Hwu W, Krown S, Menell J, et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.<Emphasis Type="Italic">J Clin Oncol</Emphasis>. 2003;21:3351–3356.</BibUnstructured>
              </Citation>
              <Citation ID="CR15">
                <CitationNumber>15.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>W</Initials>
                    <FamilyName>Maples</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Stevenson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Sumrall</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Naughton</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Schwartz</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Advanced pancreatic cancer: a multi-institutional trial with gemcitabine and thalidomide</ArticleTitle>
                  <JournalTitle>J Clin Oncol</JournalTitle>
                  <VolumeID>22</VolumeID>
                  <FirstPage>4082</FirstPage>
                  <LastPage>4082</LastPage>
                </BibArticle>
                <BibUnstructured>Maples W, Stevenson J, Sumrall S, Naughton M, Schwartz J. Advanced pancreatic cancer: a multi-institutional trial with gemcitabine and thalidomide.<Emphasis Type="Italic">J Clin Oncol</Emphasis>. 2004;22:4082.</BibUnstructured>
              </Citation>
              <Citation ID="CR16">
                <CitationNumber>16.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>IM</Initials>
                    <FamilyName>Ghobrial</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SV</Initials>
                    <FamilyName>Rajkumar</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Management of thalidomide toxicity</ArticleTitle>
                  <JournalTitle>J Support Oncol</JournalTitle>
                  <VolumeID>1</VolumeID>
                  <FirstPage>194</FirstPage>
                  <LastPage>205</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15334875</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXot1Wis7o%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity.<Emphasis Type="Italic">J Support Oncol</Emphasis>. 2003;1:194–205.</BibUnstructured>
              </Citation>
              <Citation ID="CR17">
                <CitationNumber>17.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Corral</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Kaplan</FamilyName>
                  </BibAuthorName>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">Immunomodulation by thalidomide and thalidomide analogues</ArticleTitle>
                  <JournalTitle>Ann Rheum Dis</JournalTitle>
                  <VolumeID>58</VolumeID>
                  <IssueID>Suppl. 1</IssueID>
                  <FirstPage>1107</FirstPage>
                  <LastPage>1113</LastPage>
<Occurrence Type="DOI">
<Handle>10.1136/ard.58.2008.i107</Handle>
</Occurrence>
                </BibArticle>
                <BibUnstructured>Corral L, Kaplan G. Immunomodulation by thalidomide and thalidomide analogues.<Emphasis Type="Italic">Ann Rheum Dis</Emphasis>. 1999;58:(Suppl. 1),1107–1113.</BibUnstructured>
              </Citation>
              <Citation ID="CR18">
                <CitationNumber>18.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Sampaio</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Sarno</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Gallily</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Z</Initials>
                    <FamilyName>Cohn</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Kaplan</FamilyName>
                  </BibAuthorName>
                  <Year>1991</Year>
                  <ArticleTitle Language="En">Thalidomide selectively inhibits tumor necrosis factor a production by stimulated human monocytes</ArticleTitle>
                  <JournalTitle>J Exp Med</JournalTitle>
                  <VolumeID>173</VolumeID>
                  <FirstPage>699</FirstPage>
                  <LastPage>703</LastPage>
                  <Occurrence Type="PID">
                    <Handle>1997652</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1084/jem.173.3.699</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK3MXhsFKku70%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Sampaio E, Sarno E, Gallily R, Cohn Z, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor a production by stimulated human monocytes.<Emphasis Type="Italic">J Exp Med</Emphasis>. 1991;173:699–703.</BibUnstructured>
              </Citation>
              <Citation ID="CR19">
                <CitationNumber>19.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>GW</Initials>
                    <FamilyName>Muller</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Chen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SY</Initials>
                    <FamilyName>Huang</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production</ArticleTitle>
                  <JournalTitle>Bioorg Med Chem Lett.</JournalTitle>
                  <VolumeID>9</VolumeID>
                  <FirstPage>1625</FirstPage>
                  <LastPage>1630</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10386948</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0960-894X(99)00250-4</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1MXjvVKisbs%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Muller GW, Chen R, Huang SY, et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production.<Emphasis Type="Italic">Bioorg Med Chem Lett.</Emphasis>, 1999;9:1625–1630.</BibUnstructured>
              </Citation>
              <Citation ID="CR20">
                <CitationNumber>20.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Munshi</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Recent advances in the management of multiple myeloma</ArticleTitle>
                  <JournalTitle>Semin Hematol</JournalTitle>
                  <VolumeID>41</VolumeID>
                  <FirstPage>21</FirstPage>
                  <LastPage>26</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15190512</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1053/j.seminhematol.2004.03.002</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXltV2lurY%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Munshi N. Recent advances in the management of multiple myeloma.<Emphasis Type="Italic">Semin Hematol</Emphasis>. 2004;41:21–26.</BibUnstructured>
              </Citation>
              <Citation ID="CR21">
                <CitationNumber>21.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Richardson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Schlossman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Anderson</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma</ArticleTitle>
                  <JournalTitle>Blood</JournalTitle>
                  <VolumeID>100</VolumeID>
                  <FirstPage>3063</FirstPage>
                  <LastPage>3067</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12384400</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1182/blood-2002-03-0996</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XosVSis78%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Richardson P, Schlossman R, Anderson K. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.<Emphasis Type="Italic">Blood</Emphasis>. 2002;100:3063–3067.</BibUnstructured>
              </Citation>
              <Citation ID="CR22">
                <CitationNumber>22.</CitationNumber>
                <BibUnstructured>Mufti G, List A, Gore S, Ho A. Myelodysplastic syndrome.<Emphasis Type="Italic">Hematology (Am Soc Hematol Educ Program)</Emphasis>. 2003;:176–199.</BibUnstructured>
              </Citation>
              <Citation ID="CR23">
                <CitationNumber>23.</CitationNumber>
                <BibUnstructured>List A, Kurtin S, Glinsmann-Gibson B, et al. Efficacy and safety of CC-5013 for treatment of anemia in patients with myelodysplastic syndrome (MDS).<Emphasis Type="Italic">Blood</Emphasis>. 2003; 102: Abstract 641.</BibUnstructured>
              </Citation>
              <Citation ID="CR24">
                <CitationNumber>24.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Sison</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Bond</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Amato</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Crawford</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Crighton</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Phase II of CC-4047 in patients with metastatic hormone-refractory prostate cancer</ArticleTitle>
                  <JournalTitle>J Clin Oncol</JournalTitle>
                  <VolumeID>22</VolumeID>
                  <FirstPage>4701</FirstPage>
                  <LastPage>4701</LastPage>
                </BibArticle>
                <BibUnstructured>Sison B, Bond T, Amato R, Crawford D, Crighton F. Phase II of CC-4047 in patients with metastatic hormone-refractory prostate cancer.<Emphasis Type="Italic">J Clin Oncol</Emphasis>. 2004;22:4701.</BibUnstructured>
              </Citation>
              <Citation ID="CR25">
                <CitationNumber>25.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Corral</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Muller</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Moreira</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1996</Year>
                  <ArticleTitle Language="En">Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity</ArticleTitle>
                  <JournalTitle>Mol Med</JournalTitle>
                  <VolumeID>2</VolumeID>
                  <FirstPage>506</FirstPage>
                  <LastPage>515</LastPage>
                  <Occurrence Type="PID">
                    <Handle>8827720</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK28XltVegsr0%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Corral L, Muller G, Moreira A, et al. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity.<Emphasis Type="Italic">Mol Med</Emphasis>. 1996;2:506–515.</BibUnstructured>
              </Citation>
              <Citation ID="CR26">
                <CitationNumber>26.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Moreira</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Sampaio</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Zmuidzinas</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Frindt</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Smith</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Kaplan</FamilyName>
                  </BibAuthorName>
                  <Year>1993</Year>
                  <ArticleTitle Language="En">Thalidomide exerts its inhibitory action on TNF-alpha by enhancing mRNA degradation</ArticleTitle>
                  <JournalTitle>J Exp Med</JournalTitle>
                  <VolumeID>177</VolumeID>
                  <FirstPage>1675</FirstPage>
                  <LastPage>1680</LastPage>
                  <Occurrence Type="PID">
                    <Handle>8496685</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1084/jem.177.6.1675</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK3sXitVCqsrY%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Moreira A, Sampaio E, Zmuidzinas A, Frindt P, Smith K, Kaplan G. Thalidomide exerts its inhibitory action on TNF-alpha by enhancing mRNA degradation.<Emphasis Type="Italic">J Exp Med</Emphasis>. 1993;177:1675–1680.</BibUnstructured>
              </Citation>
              <Citation ID="CR27">
                <CitationNumber>27.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Corral</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Haslett</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Muller</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">Differential cytokine modulation and T cell activation by 2 distinct classes of thalidomide analogues that are potent inhibitors of TNF-α</ArticleTitle>
                  <JournalTitle>J Immunol</JournalTitle>
                  <VolumeID>163</VolumeID>
                  <FirstPage>380</FirstPage>
                  <LastPage>386</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10384139</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1MXkt1SisLw%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Corral L, Haslett P, Muller G, et al. Differential cytokine modulation and T cell activation by 2 distinct classes of thalidomide analogues that are potent inhibitors of TNF-α.<Emphasis Type="Italic">J Immunol</Emphasis>. 1999;163:380–386.</BibUnstructured>
              </Citation>
              <Citation ID="CR28">
                <CitationNumber>28.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Haslett</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Corral</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Albert</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Kaplan</FamilyName>
                  </BibAuthorName>
                  <Year>1998</Year>
                  <ArticleTitle Language="En">Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset</ArticleTitle>
                  <JournalTitle>J Exp Med</JournalTitle>
                  <VolumeID>187</VolumeID>
                  <FirstPage>1885</FirstPage>
                  <LastPage>1982</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9607928</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1084/jem.187.11.1885</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1cXjs1eht7k%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Haslett P, Corral L, Albert A, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset.<Emphasis Type="Italic">J Exp Med</Emphasis>. 1998;187:1885–1982.</BibUnstructured>
              </Citation>
              <Citation ID="CR29">
                <CitationNumber>29.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Bartlett</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Dredge</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Dalgleish</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">The evolution of thalidomide and its IMiD<Superscript>®</Superscript> derivatives as anti-cancer agents</ArticleTitle>
                  <JournalTitle>Nat Rev Cancer</JournalTitle>
                  <VolumeID>4</VolumeID>
                  <FirstPage>314</FirstPage>
                  <LastPage>322</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15057291</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/nrc1323</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXis1Gmt7k%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bartlett J, Dredge K, Dalgleish A. The evolution of thalidomide and its IMiD<Superscript>®</Superscript> derivatives as anti-cancer agents.<Emphasis Type="Italic">Nat Rev Cancer</Emphasis>. 2004;4:314–322.</BibUnstructured>
              </Citation>
              <Citation ID="CR30">
                <CitationNumber>30.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Geitz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Handt</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Zwingenberger</FamilyName>
                  </BibAuthorName>
                  <Year>1996</Year>
                  <ArticleTitle Language="En">Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade</ArticleTitle>
                  <JournalTitle>Immunopharmacology</JournalTitle>
                  <VolumeID>31</VolumeID>
                  <FirstPage>213</FirstPage>
                  <LastPage>221</LastPage>
                  <Occurrence Type="PID">
                    <Handle>8861747</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0162-3109(95)00050-X</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK28XhvVKks7s%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade.<Emphasis Type="Italic">Immunopharmacology</Emphasis>. 1996;31:213–221.</BibUnstructured>
              </Citation>
              <Citation ID="CR31">
                <CitationNumber>31.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>A.</Initials>
                    <FamilyName>Verbon</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Juffermans</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Speelman</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans</ArticleTitle>
                  <JournalTitle>Antimicrob Agents Chemother</JournalTitle>
                  <VolumeID>44</VolumeID>
                  <FirstPage>2286</FirstPage>
                  <LastPage>2290</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10952569</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1128/AAC.44.9.2286-2290.2000</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXmtFylsLs%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Verbon A., Juffermans N, Speelman P, et al. A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans.<Emphasis Type="Italic">Antimicrob Agents Chemother</Emphasis>. 2000;44:2286–2290.</BibUnstructured>
              </Citation>
              <Citation ID="CR32">
                <CitationNumber>32.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Dredge</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Marriott</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Todryk</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity</ArticleTitle>
                  <JournalTitle>J Immunol</JournalTitle>
                  <VolumeID>168</VolumeID>
                  <FirstPage>3914</FirstPage>
                  <LastPage>3919</LastPage>
<Occurrence Type="DOI">
<Handle>10.4049/jimmunol.168.10.4914</Handle>
</Occurrence>
                </BibArticle>
                <BibUnstructured>Dredge K, Marriott J, Todryk S, et al. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity.<Emphasis Type="Italic">J Immunol</Emphasis>. 2002;168:3914–3919.</BibUnstructured>
              </Citation>
              <Citation ID="CR33">
                <CitationNumber>33.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Oliver</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">The Th1/Th2 paradigm in the pathogenesis of scleroderma and its modulation by thalidomide</ArticleTitle>
                  <JournalTitle>Curr Rheumatol Rep</JournalTitle>
                  <VolumeID>2</VolumeID>
                  <FirstPage>486</FirstPage>
                  <LastPage>491</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11123102</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/s11926-000-0025-7</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD38%2FgsF2ltQ%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Oliver S. The Th1/Th2 paradigm in the pathogenesis of scleroderma and its modulation by thalidomide.<Emphasis Type="Italic">Curr Rheumatol Rep</Emphasis>. 2000;2:486–491.</BibUnstructured>
              </Citation>
              <Citation ID="CR34">
                <CitationNumber>34.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>PH</Initials>
                    <FamilyName>Schafer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AK</Initials>
                    <FamilyName>Gandhi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MA</Initials>
                    <FamilyName>Loveland</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs</ArticleTitle>
                  <JournalTitle>J Pharmacol Exp Ther</JournalTitle>
                  <VolumeID>305</VolumeID>
                  <FirstPage>1222</FirstPage>
                  <LastPage>1232</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12649301</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1124/jpet.102.048496</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXkt1SntL4%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Schafer PH, Gandhi AK, Loveland MA, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2003;305:1222–1232.</BibUnstructured>
              </Citation>
              <Citation ID="CR35">
                <CitationNumber>35.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Davies</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Raje</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Hideshima</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma</ArticleTitle>
                  <JournalTitle>Blood</JournalTitle>
                  <VolumeID>98</VolumeID>
                  <FirstPage>210</FirstPage>
                  <LastPage>216</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11418482</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1182/blood.V98.1.210</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXkvFSlsrk%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Davies F, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.<Emphasis Type="Italic">Blood</Emphasis>. 2001; 98:210–216.</BibUnstructured>
              </Citation>
              <Citation ID="CR36">
                <CitationNumber>36.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>D'Amato</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Loughnan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Flynn</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Folkman</FamilyName>
                  </BibAuthorName>
                  <Year>1994</Year>
                  <ArticleTitle Language="En">Thalidomide is an inhibitor of angiogenesis</ArticleTitle>
                  <JournalTitle>Proc Natl Acad Sci USA</JournalTitle>
                  <VolumeID>91</VolumeID>
                  <FirstPage>4082</FirstPage>
                  <LastPage>4085</LastPage>
                  <Occurrence Type="PID">
                    <Handle>7513432</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1073/pnas.91.9.4082</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>D'Amato R, Loughnan M, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 1994;91:4082–4085.</BibUnstructured>
              </Citation>
              <Citation ID="CR37">
                <CitationNumber>37.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Dredge</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Marriott</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Macdonald</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects</ArticleTitle>
                  <JournalTitle>Br J Cancer</JournalTitle>
                  <VolumeID>87</VolumeID>
                  <FirstPage>1166</FirstPage>
                  <LastPage>1172</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12402158</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/sj.bjc.6600607</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XotFWrurk%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Dredge K, Marriott J, Macdonald C, et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects.<Emphasis Type="Italic">Br J Cancer</Emphasis>. 2002; 87:1166–1172.</BibUnstructured>
              </Citation>
              <Citation ID="CR38">
                <CitationNumber>38.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Gupta</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Treon</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Shima</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications</ArticleTitle>
                  <JournalTitle>Leukemia</JournalTitle>
                  <VolumeID>15</VolumeID>
                  <FirstPage>1950</FirstPage>
                  <LastPage>1961</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11753617</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XivVyqtg%3D%3D</Handle>
                  </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1038/sj.leu.2402295</Handle>
</Occurrence>
                </BibArticle>
                <BibUnstructured>Gupta D, Treon S, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.<Emphasis Type="Italic">Leukemia</Emphasis>. 2001;15:1950–1961.</BibUnstructured>
              </Citation>
              <Citation ID="CR39">
                <CitationNumber>39.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Hideshima</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Chauhan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Shima</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Thalidomide and its analog overcome drug resistance of human multiple myeloma cells to conventional therapy</ArticleTitle>
                  <JournalTitle>Blood</JournalTitle>
                  <VolumeID>96</VolumeID>
                  <FirstPage>2943</FirstPage>
                  <LastPage>2950</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11049970</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXnslGnsbw%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analog overcome drug resistance of human multiple myeloma cells to conventional therapy.<Emphasis Type="Italic">Blood</Emphasis>. 2000;96:2943–2950.</BibUnstructured>
              </Citation>
              <Citation ID="CR40">
                <CitationNumber>40.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Mitsiades</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Mitsiades</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>V</Initials>
                    <FamilyName>Poulaki</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications</ArticleTitle>
                  <JournalTitle>Blood</JournalTitle>
                  <VolumeID>99</VolumeID>
                  <FirstPage>4525</FirstPage>
                  <LastPage>4530</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12036884</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1182/blood.V99.12.4525</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XksFGksL4%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Mitsiades N, Mitsiades C, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.<Emphasis Type="Italic">Blood</Emphasis>. 2002;99:4525–4530.</BibUnstructured>
              </Citation>
            </Bibliography>
          </ArticleBackmatter>
        </Article>
      </Issue>
    </Volume>
  </Journal>
</Publisher>
